(PRWEB) July 28, 2014
PTSD (Post Traumatic Stress Disorder) among military men and women is prevalent, with over 10,000 new cases diagnosed each year, some requiring hospitalization. A link between PTSD and high homocysteine – an amino acid – has been validated in many studies. Many things can contribute to high homocysteine, including extreme stress, as would be expected in PTSD, and genetic issues such as the MTHFR polymorphism. A critical combination of B vitamins and co-factors is needed to keep homocysteine in a healthy range, and when elevated, it can lead to cardiovascular disease, stroke, dementia, and a host of other health problems.
One study published by Levine, et al. in Depression and Anxiety found "the duration of PTSD was found to predict serum homocysteine levels. Our results suggest that elevated levels of homocysteine in male patients with PTSD may be related to pathophysiological aspects associated with the chronicity of this disorder." Another study published by Jendricko, et al. in Progress in NeuroPsychopharmacology & Biological Psychiatry found homocysteine levels significantly higher in men with PTSD than in those without.
Antidepresssants and cognitive therapy are the most common ways to treat this disorder. Adding a homocysteine-lowering agent to this regimen would help improve symptoms and overall health long term. There is only one patented drug containing all of the necessary ingredients to lower homocysteine – EnLyte with Delta Folate. This is a new, natural, advanced generation folate therapy containing all natural, unique, and reduced folates and co-factors, as well as other minerals for overall brain health. It may be used alone or added to an SSRI/SNRI. With both the depression and hyperhomocysteinemia indications, this new drug has huge potential to assist in the military arena:
To learn more, visit http://www.EnlyteRx.Com.